Moderna shares jump 9% on leadership reshuffle and 2027-28 vaccine launch plans

Moderna stock surged 9% to nearly $57, marking a 94% gain year-to-date, driven by a leadership restructuring aimed at preparing for multiple vaccine launches in 2027 and 2028. The company expanded President Stephen Hoge's role and appointed Ester Banque as Chief Commercial Officer to support commercialization efforts. This move aligns with upcoming product launches, including a flu-plus-COVID combo vaccine and a seasonal flu vaccine, boosting investor confidence. However, Moderna faces risks from recent litigation charges and regulatory hurdles, with key FDA advisory votes upcoming in June and August that could impact the stock's momentum.